SS-31

SS-31 (Elamipretide, also known as MTP-131 and Bendavia) is a tetrapeptide mitochondria-targeting compound developed through the research of Hazel Szeto at Cornell University. It belongs to the Szeto-Schiller family of peptides, designed with specific structural features that allow them to penetrate cell membranes and concentrate within the inner mitochondrial membrane — a biologically unique and therapeutically critical location. SS-31 is currently the most advanced mitochondria-targeting peptide in clinical development, with active Phase III clinical trials for heart failure and other conditions of mitochondrial dysfunction.

The inner mitochondrial membrane is the site of the electron transport chain (ETC) — the machinery that generates approximately 95% of the body's ATP through oxidative phosphorylation. The efficiency and integrity of the ETC is dependent on the organization of the inner mitochondrial membrane, which in turn depends critically on cardiolipin — a specialized phospholipid found almost exclusively in the inner mitochondrial membrane that anchors ETC complexes in their functional arrangements. With aging, ischemia, heart failure, and other disease states, cardiolipin undergoes oxidative damage that disrupts ETC complex organization, causing increased oxidative stress, reduced ATP synthesis, and a destructive cycle of mitochondrial dysfunction. SS-31 has extremely high affinity for cardiolipin and concentrates at the inner mitochondrial membrane where it directly interacts with cardiolipin, protecting it from oxidative modification, restoring ETC complex superstructure (supercomplexes), and improving electron transfer efficiency.

The clinical trial results to date are among the most compelling for any mitochondria-targeting therapeutic. In the STEMI-BTF trial (ST-elevation myocardial infarction), SS-31 administered during reperfusion showed significant reduction in infarct size compared to placebo — a result with profound implications given that reperfusion injury (paradoxical damage that occurs when blood flow is restored to ischemic tissue) is mediated substantially by mitochondrial ROS release. In the ELITE trial for heart failure with preserved ejection fraction (HFpEF), SS-31 improved exercise capacity and reduced cardiac biomarkers in a population with very few effective treatment options. The MMPOWER-3 trial in Barth syndrome (a rare genetic mitochondrial disease) showed functional improvement. Across multiple cardiovascular indications, SS-31's profile as a mitochondrial protective agent is consistently supported.

For performance and longevity applications, the mitochondrial optimization mechanism translates to practical benefits that track directly with mitochondrial health: enhanced aerobic capacity (mitochondria are the limiting factor in oxidative energy production), reduced exercise-induced oxidative stress (which contributes to delayed recovery and long-term mitochondrial damage from heavy training), improved cellular energy availability during high-demand states, and potential protection against the progressive mitochondrial dysfunction that underlies age-related decline in energy and exercise capacity. The compound remains in research-use territory for these applications, but the clinical development pathway provides an unusually well-characterized scientific foundation.